John Newcomb
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Protein Kinase Regulation and GTPase Signaling, Synthesis and biological activity, Cancer-related Molecular Pathways, Glycosylation and Glycoproteins Research
Most-Cited Works
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides(1992)379 cited
- → Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors(1999)255 cited
- → Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor(2017)223 cited
- → Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles.(1995)145 cited
- → Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers(1993)143 cited
- → Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors(2013)76 cited
- → Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity(2006)67 cited
- → Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity(2008)63 cited
- → Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck: Synthesis, SAR, and in Vivo Antiinflammatory Activity(2006)61 cited